Screening for Type 2 Diabetes Author: Lorraine Lipscombe, MD, FRCPC; Denice S. Feig, MD, MSc, FRCPC
Editorial changes - 2010-01-07
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Screening Tests
Effectiveness/Harms of Early Treatment
Direct Evidence that Screening Reduces Adverse Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines
Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Frequently Asked Questions
Population at Risk
Should asymptomatic adults be screened for diabetes?
At what age should screening be started?
Who are high-risk individuals and how should they be screened?
Effectiveness/Harms of Screening Tests
What is the sensitivity and specificity of the FBG test?
When should the OGTT be used to diagnose diabetes?
Can the HbA1c be used to screen for diabetes?
Effectiveness/Harms of Early Treatment
Does intensive glycemic control in persons with newly diagnosed type 2 diabetes reduce long-term complications of diabetes?
Is BP control beneficial in persons with type 2 diabetes?
Should all patients with diabetes be treated with an HMG-CoA reductase inhibitor (statin)?
What are the adverse effects of intensive glycemic control in newly diagnosed type 2 diabetes?
Are there harms associated with BP control in patients with diabetes?
What are the side effects of statin therapy?
Direct Evidence that Screening Reduces Adverse Outcomes
Is there any evidence that screening for diabetes reduces long-term complications of diabetes?
Is there any evidence that screening for impaired glucose tolerance or impaired fasting glucose reduces the progression to diabetes?
Timeline
How often should screening for diabetes be done?
When should screening be discontinued?
Cost-Effectiveness
Is screening for diabetes cost-effective?
Are there populations in which screening for diabetes is more cost-effective?
Patient Education
Are there patient education strategies that affect screening for diabetes?
Does patient education reduce progression to diabetes in patients at risk for diabetes?
Does patient education improve outcomes for patients with diabetes?
Referral/Consultation
When should patients diagnosed with diabetes be referred to a diabetes specialist?
| Patient Information
Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.